Company Overview

Profusa, Inc. is a medical technology company focused on developing implantable, tissue-integrated biosensors designed for continuous, real-time monitoring of physiological parameters. The company operates within the medical devices, biotechnology, and digital health industries, with an emphasis on chronic disease management, clinical research, and pharmaceutical development. Profusa’s core technology centers on injectable hydrogel-based sensors that integrate with tissue and can be read non-invasively using optical devices.

The company’s primary products and revenue drivers are its biosensing platforms, including systems designed to measure tissue oxygenation and metabolic biomarkers such as glucose. These technologies are targeted at pharmaceutical and biotechnology companies, clinical research organizations, and government and defense agencies for use in drug development, clinical trials, and health monitoring. Profusa positions itself uniquely through its minimally invasive, long-duration sensing capability, which differentiates it from traditional wearable or short-term implantable sensors. The company was founded in 2009, originating from academic research, and has since evolved from early-stage R&D into clinical validation and pilot commercial deployments.

Business Operations

Profusa’s operations are centered on research, development, and validation of its biosensor platforms, with revenue generation primarily linked to research contracts, development partnerships, and early commercial engagements. Its core business units include the Profusa Oxygen Platform and Profusa Metabolic Sensing Platform, which are designed for use in both clinical and research settings. The company does not publicly report diversified operating segments in the manner of large public corporations, reflecting its focus on a concentrated technology portfolio.

Operationally, Profusa conducts the majority of its activities in the United States, including sensor development, preclinical and clinical studies, and regulatory engagement. The company controls proprietary hydrogel sensor technology, optical reader systems, and associated software. It has worked with U.S. government agencies, including defense-related research programs, to support human performance and health monitoring initiatives. Public information on subsidiaries, joint ventures, or extensive commercial partnerships is limited; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Profusa is focused on expanding the clinical applicability and regulatory acceptance of its implantable biosensors. Growth initiatives emphasize advancing clinical trials, securing regulatory clearances, and integrating its sensing platforms into pharmaceutical development workflows. The company has publicly highlighted its intention to support decentralized and data-rich clinical trials through continuous biomarker monitoring.

Profusa has received non-dilutive funding and research support through government contracts and grants, particularly in areas related to human performance and resilience. There is no publicly verified information indicating large-scale acquisitions or a portfolio of operating subsidiaries. Investment activity appears concentrated on internal technology development rather than external acquisitions. Engagement in emerging sectors such as continuous biomarker monitoring, implantable biosensing, and precision medicine is central to the company’s long-term strategy.

Geographic Footprint

Profusa is headquartered in South San Francisco, California, a major hub for biotechnology and medical device innovation. Its primary operational footprint is within the United States, where research, development, and clinical collaborations are conducted.

Internationally, Profusa’s influence is primarily indirect, through potential participation in multinational clinical trials and collaborations with global pharmaceutical companies. However, publicly available information does not confirm significant foreign subsidiaries or permanent international operations. As such, the company’s geographic footprint remains predominantly North American, with global reach tied to partner-led research activities.

Leadership & Governance

Profusa was founded by Ben Hwang, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes a mission-driven philosophy focused on translating advanced biomaterials research into practical clinical tools that improve patient monitoring and healthcare outcomes.

Key executives include:

• Ben Hwang – Founder and Chief Executive Officer

Public disclosures consistently identify Ben Hwang as the primary executive leader. Information on additional named executive officers or a broader executive management team cannot be consistently verified across multiple independent public sources; data inconclusive based on available public sources. The company is governed as an independent corporate entity, with strategic oversight aligned to long-term technology development and clinical adoption rather than short-term financial performance.